Market access update
Avalere’s Healthcare Industry Outlook Report 2023

With significant changes on the horizon, now is the time to define your organization’s 2023 strategy. We hope the insights in Avalere’s Healthcare Industry Outlook report will help you identify your business priorities and bring clarity to your possibilities.
Shaping the future: Inflation Reduction Act (IRA) implementation
As the industry prepares for the Inflation Reduction Act’s landmark policy changes, healthcare stakeholders realize that its wide-ranging effects will require new approaches to drug pricing, health plan design, and investment.
Challenging the standard: rethinking quality and value
At the same time, the continued focus on quality and the value of care – whether provided by hospitals and health plans or via prescription drugs and devices – is not only underscoring the need for strong evidence but also creating new imperatives for evidence generation.
Covering new ground: accessing healthcare in the community
In this year’s Healthcare Industry Outlook report, the experts at Avalere also examine how community-wide healthcare will be affected by a recent US court ruling and consider the role of data in addressing health disparities. In addition, as the healthcare system emerges from the COVID-19 pandemic and the economic outlook remains uncertain, we anticipate the continued evolution of the health insurance landscape and access to care.
Supporting your Policy, Access, Value, and Evidence needs
Avalere and PRMA Consulting are part of Fishawack Health, a leading global commercialization partner for the biopharmaceutical, medical technology, and wellness industries. We make it our business to understand our clients’ expectations and exceed them, please get in touch for a confidential conversation.

FREE Ebook
Integrated evidence generation 2.0: A strategy for every stakeholder
The data you submit here will be processed by us, and our partners within Fishawack Health, as outlined in our privacy policy, cookie policy, and terms and conditions.
Latest insights


